Letters to the Editor

Spontaneous remission of Merkel cell carcinoma presenting with tertiary lymphoid structures in an immunocompetent patient

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 15 May 2026
77
Views
18
Downloads

Authors

Dear Editor,

Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer predominantly affecting elderly males, with a median age at diagnosis of 76 years. Its pathogenesis is linked to three main risk factors: UV exposure, Merkel cell polyomavirus (MCPyV) infection, and immunosuppression. Standard management of localized disease (stage I/II) consists of wide local excision with sentinel lymph node biopsy (SLNB), followed by adjuvant radiotherapy according to disease stage. Despite optimal multimodal treatment, prognosis remains poor, with more than 50% of patients progressing to metastatic disease and a median overall survival of approximately 20 months with first-line avelumab. [...]

Downloads

Download data is not yet available.

Citations

1. Schadendorf D, Lebbé C, Zur Hausen A, et al. Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer 2017;71:53-69.
2. Lugowska I, Becker JC, Ascierto PA, et al; ESMO Guidelines Committee. Merkel-cell carcinoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment, and follow-up. ESMO Open 2024;9:102977.
3. Levy S, Aarts MJB, Eskens FALM, et al. Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort. J Immunother Cancer 2020;8:e001076.
4. D’Angelo SP, Lebbé C, Mortier L, et al. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. J Immunother Cancer 2021;9:e002646.
5. Okamoto O, Yoshiyama M, Takayasu S, Yokoyama S. Merkel cell carcinoma: report of three cases. J Dermatol 1998;25:45-50.
6. Gamissans M, Muntaner-Virgili C, Penín RM, Marcoval J. Characteristics of spontaneous regression of Merkel cell carcinoma: a retrospective analysis of patient and tumour features. Clin Exp Dermatol 2025;50:994-7.
7. Branch S, Maloney K, Purcell SM. Spontaneous regression of Merkel cell carcinoma. Cutis 2018;101:301-5.
8. Nakamura M, Yoshimitsu M, Magara T, et al. Analyses of tertiary lymphoid structures observed in cases of Merkel cell carcinoma showing spontaneous regression. Exp Dermatol 2024;33:e15062.
9. Srinivas N, Spassova I, Lei KC, et al. Tertiary lymphoid structures in Merkel cell carcinoma facilitate naïve and central memory T-cell infiltration linked to immunotherapy response. J Immunother Cancer 2025;13:e012224.

How to Cite



1.
Cerbone L, Garau A, Borra T, Barbieri P, Parisi R, Leporati C, et al. Spontaneous remission of Merkel cell carcinoma presenting with tertiary lymphoid structures in an immunocompetent patient. Dermatol Reports [Internet]. 2026 May 15 [cited 2026 May 19];. Available from: https://journals.pagepress.net/dr/article/view/10799